Analysts have been eager to weigh in on the Healthcare sector with new ratings on Addus Homecare (ADUS – Research Report), BioCryst (BCRX – Research Report) and Syndax Pharmaceuticals (SNDX – Research Report).
Addus Homecare (ADUS)
In a report released today, Andrew Mok CFA from Barclays assigned a Sell rating to Addus Homecare, with a price target of $83.00. The company’s shares closed last Monday at $97.89.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Addus Homecare with a $110.14 average price target.
See the top stocks recommended by analysts >>
BioCryst (BCRX)
Barclays analyst Gena Wang maintained a Hold rating on BioCryst today and set a price target of $6.00. The company’s shares closed last Monday at $5.27.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $15.38.
Syndax Pharmaceuticals (SNDX)
In a report released today, Peter Lawson from Barclays assigned a Buy rating to Syndax Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Monday at $22.50.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Syndax Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $33.44, implying a 51.1% upside from current levels. In a report issued on April 28, Citi also maintained a Buy rating on the stock with a $32.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADUS:
- Addus Homecare Releases Quarterly Financial Results
- Addus HomeCare Corporation (ADUS) Q1 Earnings Cheat Sheet
- Roblox upgraded, Qualcomm initiated: Wall Street’s top analyst calls
- Barclays downgrades Addus to Underweight on ‘materially negative’ regulation
- Addus HomeCare falls 4% after HHS announced Medicaid Services rule
